Options market sees Celladon heart drug as all-or-nothing bet

April 17, 2015 7:57 PM

9 0

NEW YORK (Reuters) - Celladon Corp's shares could either double in value or collapse over the next four weeks after the drug developer announces results from a heart failure gene therapy trial, options data shows.

Later this month, Celladon is expected to report results from a mid-stage study of Mydicar, its experimental gene therapy for advanced heart failure, a condition in which the heart muscle cannot pump enough blood to meet the body's needs.

Also read: U.S. motor travel up 1.5 percent in April from year ago: DOT

Read more

To category page